• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study
Clin Pharmacol Ther. 2021 Jul 19. doi: 10.1002/cpt.2369. Online ahead of print.ABSTRACTConcomitant use of direct oral anticoagulants (DOACs) and medications with inhibition/induction effect on P-gp/CYP3A might increase risk of bleeding/treatment failure, respectively. We designed a nested case-control study within a Clalit cohort of atrial fibrillation (AF) patients and a cohort of venous thromboembolic patients, new users of a DOAC (1.1.2010-24.8.2020). Propensity scores were constructed from demographic, clinical and medications at cohort entry. Each case of: 1) serious bleeding event; 2) stroke/systemic emboli (SE) in A...
Source: Clinical Pharmacology and Therapeutics - July 21, 2021 Category: Drugs & Pharmacology Authors: Naomi Gronich Nilli Stein Mordehcai Muszkat Source Type: research

Abstract 151: Outcomes Associated With Prophylactic Amiodarone Protocol in Patients Undergoing Cardiac Surgery: A Single Center Experience Session Title: Poster Session I
Conclusions: Implementation of an amiodarone prophylaxis protocol order care set was associated with greater utilization of amiodarone. It was also associated with a modest decrease in the incidence of STS-defined POAF, stroke and MI but was not associated with a change in 30-day mortality in patients undergoing cardiac surgery. Further studies are needed to study the cost-effectiveness and risk-benefit analysis of routine amiodarone as prophylaxis.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Atreya, A. R., Arora, S., Garb, J., Rousou, J., Lindenauer, P., Lotfi, A. Tags: Session Title: Poster Session I Source Type: research

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
CONCLUSIONS: Several class IA, IC and III drugs, as well as class II drugs (beta-blockers), are moderately effective in maintaining sinus rhythm after conversion of atrial fibrillation. However, they increase adverse events, including pro-arrhythmia, and some of them (disopyramide, quinidine and sotalol) may increase mortality. Possible benefits on clinically relevant outcomes (stroke, embolism, heart failure) remain to be established. PMID: 25820938 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - April 2, 2015 Category: Journals (General) Authors: Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J Tags: Cochrane Database Syst Rev Source Type: research

Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin　- Insights From the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: HDE had a greater relative efficacy and safety in EA compared with Japan that was only partially explained by differences in baseline characteristics and TTR. PMID: 26460886 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 9, 2015 Category: Cardiology Authors: Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, Mercuri M, Ruff CT, Giugliano RP Tags: Circ J Source Type: research

Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis
ConclusionThe benefit-risk profile of NOACs compared to VKAs was preserved in AF patients using P-gp/CYP3A4 inhibitors, including amiodarone.
Source: Cardiovascular Drugs and Therapy - October 12, 2021 Category: Cardiology Source Type: research

Risk of Atrial Fibrillation after Atrial Flutter Ablation: Impact of AF History, Gender and Antiarrhythmic Drug Medication
ConclusionsAF occurrence after AFL ablation is frequent (>20%), especially in patients with a history of AF, in female patients, and in patients treated with Class I antiarrythmics/Amiodarone prior to AFL. Since most patients who experience AF after AFL ablation have a CHA2DS2‐VASc≥1, the decision to stop anticoagulants after ablation should be considered on an individual basis.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - March 21, 2014 Category: Cardiology Authors: BÉATRICE BREMBILLA‐PERROT, NICOLAS GIRERD, JEAN MARC SELLAL, ARNAUD OLIVIER, VLADIMIR MANENTI, THIBAUT VILLEMIN, DANIEL BEURRIER, CHRISTIAN DE CHILLOU, PIERRE LOUIS, OLIVIER SELTON, ARNAUD TERRIER DE LA CHAISE Tags: Original Article Source Type: research

Risk of Atrial Fibrillation After Atrial Flutter Ablation: Impact of AF History, Gender, and Antiarrhythmic Drug Medication
ConclusionsAF occurrence after AFL ablation is frequent (>20%), especially in patients with a history of AF, in female patients, and in patients treated with class I antiarrythmics/amiodarone prior to AFL. Since most patients who experience AF after AFL ablation have a CHA2DS2‐VASc ≥1, the decision to stop anticoagulants after ablation should be considered on an individual basis.
Source: Journal of Cardiovascular Electrophysiology - April 21, 2014 Category: Cardiology Authors: BÉATRICE BREMBILLA‐PERROT, NICOLAS GIRERD, JEAN MARC SELLAL, ARNAUD OLIVIER, VLADIMIR MANENTI, THIBAUT VILLEMIN, DANIEL BEURRIER, CHRISTIAN CHILLOU, PIERRE LOUIS, OLIVIER SELTON, ARNAUD TERRIER CHAISE Tags: Original Article Source Type: research

Abstract 374: Quality Improvement Program to Optimize Pre-Operative Evaluation of Elective Cardiovascular Surgery Patients Reduces Complications and Improves Length of Stay Session Title: Poster Session III
Conclusions: A standardized pre-operative evaluation protocol in combination with prophylactic amiodarone in appropriate patients was associated with lower overall complications and a reduction in post-operative AF and LOS. Standardized protocols may enable health care providers to optimize pre-operative management of elective surgery patients and improve care quality and outcomes.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Porten, B. R., Strauss, C. E., Mueller, J. J., Garberich, R. F., Sun, B. C., Abdelhadi, R. H., Henry, T. D. Tags: Session Title: Poster Session III Source Type: research

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research

Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
CONCLUSION: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to prevent the cardiovascular events, several risk factors should be considered before cardioversion. PMID: 26446636 [PubMed - in process]
Source: Yonsei Medical Journal - October 9, 2015 Category: Universities & Medical Training Authors: Shin DG, Cho I, Hartaigh BÓ, Mun HS, Lee HY, Hwang ES, Park JK, Uhm JS, Pak HN, Lee MH, Joung B Tags: Yonsei Med J Source Type: research

Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Conclusions -Transient symptomatic episodes of AF, although relatively uncommon in HCM, are unpredictable in frequency and timing, amenable to effective contemporary treatments, and infrequently progress to permanent AF. AF is not a major contributor to heart failure morbidity, nor a cause of arrhythmic sudden death, and when treated is associated with low-disease-related mortality, no different than for patients without AF. AF is an uncommon primary cause of death in HCM virtually limited to embolic stroke, supporting a low threshold for initiating anticoagulation therapy. PMID: 28916640 [PubMed - as supplied by publisher]
Source: Circulation - September 15, 2017 Category: Cardiology Authors: Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ Tags: Circulation Source Type: research

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018.
Authors: Brieger D, Amerena J, Attia JR, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani HM, Hendriks J, Hespe CM, Hung J, Kalman JM, Sanders P, Worthington J, Yan T, Zwar NA Abstract INTRODUCTION: Atrial fibrillation (AF) is increasing in prevalence and is associated with significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are continually evolving and care for patients requires confidence in integrating these new developments into practice. These clinical practice guidelines will assist Australian practitioners in the diagnosis and management of adult ...
Source: Medical Journal of Australia - August 3, 2018 Category: General Medicine Tags: Med J Aust Source Type: research

Pages: 1  2  3  4  5  6  7